BOSTON, Jan. 8, 2024 /PRNewswire/ Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory
- Persephone to utilize the Bacteroides technology for the rapid generation of therapeutics from its planned and ongoing biomarker studies, including the ARGONAUT study
- Ginkgo retains the rights.